JettSet1 joins Biom Therapeutics on cannabinoid Angelman treatment
JettSet1 Enterprises is partnering with preclinical stage biopharmaceutical company Biom Therapeutics to help it develop BIO017, a plant-derived cannabinoid treatment candidate for Angelman syndrome. JettSet1 has partnerships across various industries, from biotech and film to beverage and real estate. It was founded earlier this year by George…